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ABSTRACT
Long noncoding RNAs (lncRNAs) have emerged as new regulators of stem cell pluripotency and
tumorigenesis. The SOX2 gene, a master regulator of pluripotency, is embedded within the third
intron of a lncRNA known as SOX2 overlapping transcript (SOX2OT). SOX2OT has been suspected
to participate in regulation of SOX2 expression and/or other related processes; nevertheless, its
potential involvement in tumor initiation and/or progression is unclear. Here, we have evaluated a
possible correlation between expression patterns of SOX2OT and those of master regulators of plu-
ripotency, SOX2 and OCT4, in esophageal squamous cell carcinoma (ESCC) tissue samples. We have
also examined its potential function in the human embryonic carcinoma stem cell line, NTERA2
(NT2), which highly expresses SOX2OT, SOX2, and OCT4. Our data revealed a signiﬁcant coupregula-
tion of SOX2OT along with SOX2 and OCT4 in tumor samples, compared to the non-tumor tissues
obtained from the margin of same tumors. We also identiﬁed two novel splice variants of SOX2OT
(SOX2OT-S1 and SOX2OT-S2) which coupregulated with SOX2 and OCT4 in ESCCs. Suppressing
SOX2OT variants caused a profound alteration in cell cycle distribution, including a 5.9 and 6.9
time increase in sub-G1 phase of cell cycle for SOX2OT-S1 and SOX2OT-S2, respectively. The expres-
sion of all variants was signiﬁcantly diminished, upon the induction of neural differentiation in NT2
cells, suggesting their potential functional links to the undifferentiated state of the cells. Our data
suggest a part for SOX2OT spliced variants in tumor initiation and/or progression as well as regu-
lating pluripotent state of stem cells. STEM CELLS 2014;32:126–134
INTRODUCTION
Long noncoding RNAs (lncRNAs) constitute a
large portion of the human transcriptome, and
represent a new level of gene expression regula-
tion [1, 2]. LncRNAs are a diverse class of non-
coding RNAs with a size of more than 200 nt
and an expanding list of biological functions.
Among these various functions, lncRNAs are
found to be involved in epigenetic modiﬁcations
of DNA, immune signaling, and regulation of
pluripotency and differentiation processes [3–6].
Recent reports of misregulated expression
of lncRNAs across many cancer types suggest
that their aberrant expression might be a
major cause of tumorigenesis, and those
different types of cancers can be distinguished
according to their altered lncRNAs expression
signatures [7–9]. LncRNAs are also introduced
as a newly emerging class of oncogene and
tumor-suppressor genes [10].
While little evidence exists on lncRNAs
functions, their speciﬁc expression pattern, pro-
moter conservation, alternative splicing, and
association with particular chromatin signatures
all suggest that most of these transcripts are
functional [11–14]. Moreover, it is recently
claimed that lncRNAs display an enhancer-like
function in human cells [15]. They are also
implicated in the basal regulation of protein-
coding genes, including those central to normal
development and tumorigenesis, at both tran-
scriptional and post-transcriptional levels [16,
17]. To date, an increasing number of lncRNAs
have been functionally validated to affect dif-
ferent cellular pathways [18–21].
SOX2 is a HMG-box transcription factor,
which is crucial for maintaining the pluripo-
tency state and survival of human embryonic
stem cells (hESCs). Recent studies have
revealed its ampliﬁcation and activation in sev-
eral squamous cell carcinomas (SCC) [22–26].
In hESCs, Sox2 regulates the expression of
more than 1,000 gene, many of them are cor-
egulated with the other master regulator of
pluripotency such as Oct4 [27]. Interestingly,
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the intronless gene of Sox2 is embedded within the third
intron of a lncRNA gene, known as SOX2 overlapping tran-
script (SOX2OT), which is transcribed in the same orientation
as SOX2 [28]. SOX2OT has been suspected to participate in
regulation of SOX2 expression and/or related processes, but
its potential function has still remained untested [29].
NTERA2 (NT2), a human embryonal carcinoma (EC) stem
cell line, shares many features with hESCs, including similar
patterns of gene expression [30–33]. Thus, this cell type is an
excellent prototype model of pluripotent stem cells to study
gene expression and differentiation associated to human
embryonic development [34]. U-87 malignant glioblastoma (U-
87 MG) is another cell line that contains cancer stem cell-like
properties [35].
In this study, we have examined a potential correlation
between the expression patterns of SOX2OT and its novel
splice variants (SOX2OT-S1 and SOX2OT-S2), and those of mas-
ter regulators of pluripotency (SOX2 and OCT4) in esophageal
squamous cell carcinoma (ESCC). We also investigated the
function of SOX2OT novel splice variants in NT2 cells, as a
prototype model of pluripotent cells.
MATERIALS AND METHODS
Patients and Clinical Samples
Tissue biopsies were obtained from Iran national tumor bank
of Imam-Khomeini cancer institute (Tehran University of Medi-
cal Sciences). The samples had been immediately snap-frozen
in liquid nitrogen and had been stored in 270C, until being
collected for RNA extraction. The tissues were categorized in
two groups: 36 tumor samples from 36 patients with ESCC
and 36 paired non-tumor tissues (as control), which were
taken from the apparently normal tissues from the margin of
same tumors. Histopathological parameters were evaluated
according to WHO criteria for grade and TNM system for
stage classiﬁcation (Supporting Information Table S1). The
experimental design was approved by the Ethics Committees
of Tarbiat Modares University.
Cell Culture and Differentiation
The human NT2 (NTera2; kindly provided by Dr. Peter
Andrews at Shefﬁeld University) cell line was propagated in
Dulbecco’s modiﬁed Eagle’s medium (DMEM)/F-12 (Invitrogen,
Gaithersburg, MD) supplemented with 10% fetal bovine
serum (FBS; Invitrogen) and 1% penicillin/streptomycin (Sigma,
St. Louis, MO) at 37C in 5% CO2. NT2 cells were treated with
all-trans retinoic acid (ATRA, Sigma-Aldrich) to differentiate
into the neuron-like cells, according to a modiﬁed protocol
provided by Atlasi et al. [36]. Brieﬂy, 2 days before the ﬁrst
ATRA application, cells were seeded at a density of 4 3 104
cells in 2 ml growth medium per well in six-well plates. ATRA
was added to the growth medium at a ﬁnal concentration of
10 mM, and the differentiation medium was renewed twice a
week for 4 weeks at regular time intervals. Cells were then
harvested for RNA extraction, from three biological replicates
at 0, 1, 2, 3, and 4 weeks after ATRA treatment. The control
time point (t5 0) expression level was set to 100% and the
expression of the treated samples represented as a percent-
age of the control. The human malignant glioma cell line U-87
MG (derived from a malignant glioma tumor) was obtained
from Pasteur Institute (Tehran, Iran) and cultured in RPMI
medium (Sigma-Aldrich, Ltd., St. Louis, Mo.) supplemented
with 10% FBS and 1% penicillin/streptomycin, and incubated
at 37C under humidiﬁed 5% CO2.
Isolation of Nuclear and Cytoplasmic RNAs and cDNA
Synthesis
Nuclear and cytoplasmic RNAs were isolated from the human
NT2 cell line. Cells were maintained at 37C in DMEM high
glucose containing 10% FBS. After the addition of 1 ml tryp-
sin, cells were collected by centrifugation and washed by
phosphate buffered salin (PBS). The cells were then resus-
pended in 120 ml of LB buffer (10 mM NaCl, 2 mM MgCl, 10
mM Tris-HCl [pH 7.8], 5 mM dithiothreitol (DTT), and 1% Tri-
ton X-100). After centrifugation, the supernatant and pellet
were partitioned, where supernatant suspected to comprise
cytoplasmic RNA and pellet to contain nuclear RNA. The fol-
lowing steps of RNA isolation from both cell lines and
patients specimens were carried out using Trizol Reagent
(Invitrogen, Carlsbad, CA), according to the manufacturer’s
instructions. To remove any potential DNA contamination, the
extracted RNA was treated with RNase-free DNase (Takara,
Japan). The ﬁrst strand of cDNA synthesized by Reverse Tran-
scriptase (Takara, Japan), using both oligo dT and random hex-
amer primers (Takara, Japan), according to the manufacturer’s
instructions. For each sample, a no-reverse transcription (No-
RT) control was used in parallel to the DNase-treated RNA, to
detect nonspeciﬁc ampliﬁcation of genomic DNA.
RT-PCR and Quantitative Real-Time PCR
The appropriate SOX2OT PCR primers were designed using
Genrunner software (version 3.02; Hastings Software, Inc.)
and manufactured by MICROGENE Company (Supporting
Information Table S2). PCR reactions were performed using 2
ml of cDNA or No-RT samples with 1 U of Taq polymerase
(Cinnagen, Iran), 1.5 mM MgCl2, 200 mM dNTPs, and 0.5 mM
of each primer in a 20 ml PCR reaction. The PCR ampliﬁcation
was carried out using the following cycling conditions: initia-
tion at 94C for 5 minutes, ampliﬁcation for 35 cycles with
denaturation at 94C for 1 minute, annealing at 60C for 20
seconds, and extending at 72C for 1 minute and a ﬁnal
extension at 72C for 10 minutes. Direct DNA sequencing
(MICROGENE, South Korea) was performed to conﬁrm the
authenticity of the PCR products. Speciﬁc real-time PCR pri-
mers (Supporting Information Table S2) were designed for
SOX2, SOX2OT, SOX2OT-S1, SOX2OT-S2, OCT4, and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) (GenBank acces-
sion numbers: NM_003106.2, NR_004053.2, JN711430.1,
JN882275.1, NM_002701.4, NM_002046.3, respectively), using
AlleleID 6.0 software (Primer BioSoft, Palo Alto, CA; www.pre-
mierbiosoft.com) and Gene Runner software (version 3.02;
Hastings Software, Inc.). TaKaRa SYBR Premix Ex TaqII master
mix (23), supplemented with ROX reference Dye II, were
used for all real-time PCR reactions. For compensating varia-
tions in the amount of input RNA and the efﬁcacy of reverse
transcriptase, GAPDH mRNA was also quantiﬁed as an internal
control, and the expression of other genes was normalized to
its expression value. All real-time PCR reactions were carried
out with the ABI 7500 real-time PCR systems (Applied Biosys-
tems, Foster City, CA) using the following cycling conditions:
initiation at 94C for 1 minute, ampliﬁcation for 40 cycles
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